A trial of feprazone in ankylosing spondylitis.
Feprazone, a non-steroidal anti-inflammatory drug, was compared with indomethacin in a double-blind cross-over trial in 24 patients with ankylosing spondylitis, over eight weeks. Both regimes caused significant reduction in pain. There were fewer side-effects and more patient preferences with feprazone but these differences did not reach statistical significance.
D000328:Adult; D000700:Analgesics / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D011298:Feprazone / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007213:Indomethacin / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010653:Phenylbutazone / Q000031:analogs & derivatives*; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*
D000700:Analgesics; D000893:Anti-Inflammatory Agents; D011298:Feprazone; D010653:Phenylbutazone; D007213:Indomethacin